Skip to content

Effect of the Vojta Therapy in Patients Multiple Sclerosis

Effect of the Vojta Therapy on Lipid Biomarkers Related to Myelin in Subjects With Multiple Sclerosis.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05558683
Enrollment
25
Registered
2022-09-28
Start date
2022-12-01
Completion date
2023-12-01
Last updated
2022-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Keywords

Vojta Therapy, Bobath Therapy

Brief summary

Multiple sclerosis is the most common disabling neurological disease in young adults. Inflammation, demyelination, neurodegeneration, gliosis and repair processes are involved in its process, which are responsible for the heterogeneity and individual variability in the expression of the disease, the prognosis and the response to treatment. Clinically, MS manifests itself with the following symptoms: sensory focus, motor focus, spasticity, balance disorders, visual disturbances such as loss of vision or double vision or sphincter dysfunction. The main subtypes of MS are relapsing-remitting, secondary progressive, primary progressive, and progressive relapsing. Clinically, RRMS presents the initial inflammatory phase, characterized by reversible flares with neurological dysfunction, followed by periods of remission. Approximately 40-50% of these patients progress to SPMS, where the disease gradually progresses from intermittent flare-ups to steadily progressive worsening, resulting in permanent disability due to massive axonal loss. PPMS is the most severe subtype, affecting approximately 10% of all cases, and manifesting as progressive degeneration without any remission.

Detailed description

From the field of Physiotherapy, one of the main tools for the treatment of MS is physical exercise. Numerous studies show that exercising is safe and beneficial in people with MS, as long as it is done correctly and supervised by health professionals. Physical exercise is considered an important part of symptomatic and supportive treatment for people with MS, since it induces improvement of physiological functions affected by lack of physical activity and helps to manage some symptoms, such as spasticity, fatigue and lack of balance There are therapies within Physiotherapy that help treat MS such as the Vojta Method and the Bobath Method.

Interventions

OTHERRandomized clinical trial.

Our study will be a Randomized Clinical Trial. It will be held at the Aymara Abreu Physiotherapy Clinic center, with a maximum duration of 1 year. It will consist of two parts. In the first stage of the treatment we will carry out an initial assessment, and in the second stage a final assessment. After that, the corresponding data analysis will be carried out.

Sponsors

University of Salamanca
CollaboratorOTHER
Aymara Abreu Corrales
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Masking description

Our population will be subjects diagnosed with MS. Prior to the study, the informed consent will be presented to the subjects. Said confidentiality will be contemplated in Organic Law 15/99 of December 13 on the Protection of personal data.

Intervention model description

Our study will be a Randomized Clinical Trial. It will be held at the Aymara Abreu Physiotherapy Clinic center, with a maximum duration of 1 year. It will consist of two parts. In the first stage of the treatment we will carry out an initial assessment, and in the second stage a final assessment. After that, the corresponding data analysis will be carried out.

Eligibility

Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Persons with MS who have signed the informed consent. * Persons of both sexes. * Ages between 20 and 65 years. * Subjects of both sexes diagnosed with multiple sclerosis on the EDSS (Expanded Disability Status Scale).

Exclusion criteria

* Persons with multiple sclerosis with EDSS scale score equal to or greater than 7.0. * Occurrence of a flare during the period of the patient's participation in the study. * Pregnant women. * Oncology patients. * Non-acceptance and non-signing of informed consent. * Refusal to participate in the study. * Patients with severe cognitive impairment that does not allow them to understand the development of the study. * Patients with cardiovascular instability. * Patients who do not complete at least 75% of the scheduled sessions. Patients who do not present any of the contraindications contemplated for Vojta therapy.

Design outcomes

Primary

MeasureTime frameDescription
Respiratory function5 minutesRespiratory function will be assessed with a pressure manometer to measure peak inspiratory pressure.
Spasticity10 minutesSpasticity will be measured using the Tardieu scale.
Balance10 minutesThe balance will be measured through the Berg scale.
Age1 minutes
Time reaction5 minutesReaction time will be measured by the Cognifit test

Secondary

MeasureTime frameDescription
Myelin15 minutesMyelin will be me measured trough the tear duct whit phospholipid test strips

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026